Acurx Pharma Highlights MRSA Antibiotic Data Preserving Gut Microbiome

Acurx Pharmaceuticals presented new preclinical data at the 35th ESCMID Global Conference in Munich, highlighting the microbiome-preserving effects of its DNA polymerase inhibitor antibiotic compounds in an MRSA infection model. The company reported reduced MRSA tissue burden while maintaining significantly higher gut microbial diversity compared to traditional antibiotics linked to dysbiosis.

According to the company, microbiome preservation may represent a broader class effect of its DNA inhibitor platform, a potentially important development in the search for next-generation antibiotics that combat dangerous infections while minimizing disruption to beneficial gut bacteria.

#AcurxPharmaceuticals
#MRSA
#Antibiotics
#Biotech
#Microbiome
#InfectiousDisease
#HealthcareInnovation
#DrugDevelopment
#MedicalResearch
#Pharmaceuticals
#ClinicalResearch
#ESCMID
#Innovation
#JaneKing
#NewsOut